Abstract
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Loberiza FR, Zhang M-J, Lee SJ, Klein JP, LeMaistre CF, Serna DS et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979–2987.
Changsirikulchai S, Myerson D, Guthrie Kal, McDonald GB, Alpers CE, Hingorani SR . Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009; 4: 345–353.
Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK . Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22: 12–20.
Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.
Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191–204.
George JN, Selby GB . Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 2004; 33: 1073–1074.
Cho B-S, Yahng S-A, Lee S-E, Eom K-S, Kim Y-J, Kim H-J et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 918–926.
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.
Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.
Thachil J . Nitric oxide in transplantation-related thrombotic microangiopathy. Bone Marrow Transplant 2009; 43: 513–514.
Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM . The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010; 56: 1168–1174.
Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013; 96: 217–223.
Ricklin D, Cines DB . TMA: beware of complements. Blood 2013; 122: 1997–1999.
Dhakal P, Bhatt VR . Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017; 52: 352–356.
Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013; 161: 279–280.
Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20: 518–525.
Jodele S, Laskin B, Fukuda T, Vinks A, Mizuno K, Goebel J et al. Eculizumab treatment improves survival in patients with high-risk hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TMA). Biol Blood Marrow Transplant 2015; 21: S225–S226.
Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM . Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292–299.
Cohen H, Bull HA, Seddon A, Enayat MS, Hill FG, Woolf N et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989; 43: 207–214.
Nürnberger W, Michelmann I, Burdach S, Göbel U . Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61–65.
Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010; 16: 985–993.
Graf L, Stern M . Acute phase after haematopoietic stem cell transplantation: bleeding and thrombotic complications. Hamostaseologie 2012; 32: 56–62.
Tsakiris DA, Tichelli A . Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Best Pract Res Clin Haematol 2009; 22: 137–145.
Nadir Y, Brenner B . Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res 2007; 120 (Suppl): S92–S98.
Tichelli A, Gratwohl A . Vascular endothelium as “novel” target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139–148.
Nadir Y, Hoffman R, Brenner B . Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004; 8: E4.
Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638–644.
Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A . Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484–493.
Roy V, Rizvi MA, Vesely SK, George JN . Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641–646.
Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327–329.
Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525–531.
Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551–557.
Rosenthal RA, Chukwuogo NA, Ocasio VH, Kahng KU . Cyclosporine inhibits endothelial cell prostacyclin production. J Surg Res 1989; 46: 593–596.
Burke GW, Ciancio G, Cirocco R, Markou M, Olson L, Contreras N et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999; 68: 1336–1342.
Robson M, Côte I, Abbs I, Koffman G, Goldsmith D . Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324–327.
Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y . Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant 2010; 45: 689–693.
Takatsuka H, Wakae T, Mori A, Okada M, Fujimori Y, Takemoto Y et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31: 475–479.
Goon PKY, Lip GYH, Boos CJ, Stonelake PS, Blann AD . Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79–88.
Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005; 3: 1301–1308.
Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006; 81: 1405–1409.
Erdbruegger U, Woywodt A, Kirsch T, Haller H, Haubitz M . Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy. Am J Kidney Dis 2006; 48: 564–570.
Nochy D, Lefaucheur C, Hill G . VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 359: 206 author reply 206–207.
Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B . Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 942–947.
Meri S . Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013; 24: 496–502.
Noris M, Mescia F, Remuzzi G . STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622–633.
Noris M, Remuzzi G . Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–1687.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003–2007.
Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG . Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008; 85: 22–28.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Refined diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood 2014; 124: 645–654.
Kanamori H, Maruta A, Sasaki S, Yamazaki E, Ueda S, Katoh K et al. Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 1998; 21: 705–709.
Zeigler Z, Kelton J, Moore J, Shadduck R, Andrews DF, Nath R et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999; 24: 641–645.
Muto H, Ohashi K, Ando M, Akiyama H, Sakamaki H . Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2010; 91: 471–477.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645–653.
Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris Da et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 36: 993–1000.
Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112–1119.
Laskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.
Cho B-S, Min C-K, Eom K-S, Kim Y-J, Kim H-J, Lee S et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 813–820.
Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S . Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 2010; 45: 699–704.
Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN . Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009; 49: 392–394.
Thachil J . The role for adjunctive treatment to plasma exchange in thrombotic thrombocytopenic purpura. Nephrol Dial Transplant 2008; 23: 2701–22.
Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion 2013; 53: 661–667.
Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985–991.
Choi CM, Schmaier AH, Snell MR, Lazarus HM . Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009; 69: 183–198.
Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006; 38: 445–451.
Mandelbrot D . Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation. J Am Soc Nephrol 2009; 20: 1170–1171.
Dhakal P, Giri S, Pathak R, Bhatt VR . Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2017; 23: 175–180.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 307–315.
Schröder H . Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol 1995; 47: 250–252.
Au W-Y, Ma ES, Lee T-L, Ha S-Y, Fung AT, Lie AKW et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475–478.
Marr H, McDonald E-J, Merriman E, Smith M, Mangos H, Stoddart C et al. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J 2009 3 122: 72–74.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J et al. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant 2012; 16: E39–E42.
Masini E, Lupini M, Mugnai L, Raspanti S, Mannaioni PF . Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br J Pharmacol 1995; 115: 629–635.
Nishimura M, Nanbu A, Komori T, Ohtsuka K, Takahashi H, Yoshimura M . Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats. Clin Exp Pharmacol Physiol 2000; 27: 618–624.
Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101: 8497–8502.
Kajiume T, Nagita A, Yoshimi S, Kobayashi K, Kataoka N . A case of hemolytic uremic syndrome improved with nitric oxide. Bone Marrow Transplant 2000; 25: 109–110.
Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC . Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007; 293: H1115–H1121.
Inoue Y, Kosugi S, Miura I, Hatta Y, Takeuchi J . Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res 2011; 127: 603–604.
Okada K, Horino A, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y et al. [Successful treatment for thrombotic microangiopathy with recombinant human soluble thrombomodulin after umbilical cord blood transplantation]. Rinsho Ketsueki 2012; 53: 235–239.
Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015–4022.
Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 2017; 102: 466–475.
Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094–2101.
Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura J-i, Nunn MA et al. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv 2017; 1: 1254–1258.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Khosla, J., Yeh, A., Spitzer, T. et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 53, 129–137 (2018). https://doi.org/10.1038/bmt.2017.207
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.207
This article is cited by
-
Neurological involvement in hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Annals of Hematology (2024)
-
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists
Bone Marrow Transplantation (2023)
-
Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation
Scientific Reports (2023)
-
Diffuse alveolar hemorrhage: An underreported complication of transplant associated thrombotic microangiopathy
Bone Marrow Transplantation (2022)
-
Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome
Annals of Hematology (2022)